Acer Therapeutics Inc

Acer Therapeutics — Opexa Therapeutics — Investor Presentation (May 2015)

27 slides from Acer Therapeutics's investor presentation, May 12, 2015

  1. Slide 1: Opexa Therapeutics: Precision Immunotherapy

    Opexa Therapeutics, Inc. NASDAQ: OPXA Precision Immunotherapy May 2015 The Woodlands, TX Precision Immunotherapy®

  2. Slide 2: Forward-Looking Statements

    2 Forward-Looking Statements All statements in this presentation other than those of historical fact, including statements regarding our preclinical and clinical development plans for Tcelna® and OPX-212, our research and other development programs, our ability to undertake certain activities and ac

  3. Slide 3: Opexa Investment Highlights

    3 Opexa Investment Highlights PIPELINE Tcelna®: Phase 2b for secondary progressive multiple sclerosis (SPMS), limited competition, $7BN overall market potential OPX-212: Pre-IND for neuromyelitis optica (NMO), no approved therapies, orphan indication TECHNOLOGY Personalized T-cell immunotherapy plat

  4. Slide 4: Recent and Upcoming Expected Milestones

    4 Recent and Upcoming Expected Milestones Tcelna: Multiple Sclerosis 1H 2014: Completed Enrollment in Phase 2b SPMS trial Q1 2015: Received additional $3M payment from Merck Serono for Tcelna development 2H 2016: Top line results expected for Abili-T Phase 2b SPMS trial OPX-212: Neuromyelitis Optica

  5. Slide 5: Financials

    Financials (1)Weighted average exercise price =$4.08 as of March 31, 2015. Excludes 25,098,437 warrants issued as part of the rights offering completed in April 2015 (2)As part of the rights offering an additional 25,098,437 warrants were issued (exercise price = $0.50 through 06/30/16 and $1.50 fro

  6. Slide 6: How Does Tcelna Work?

    ‘ee OPEXA HOW DOES TCELNA WORK?

  7. Slide 7: The Root Cause of Multiple Sclerosis: Activated T-cells Degrade Myelin

    7 The Root Cause of Multiple Sclerosis: Activated T- cells Degrade Myelin and Damage Myelin Producing Cells Adapted by permission from Macmillan Publishers Ltd: NATURE REVIEWS IMMUNOLOGY 3, 483-492 (June 2003), copyright (2003) Cytokines Damage Damage In MS patients, the faulty immune system is not

  8. Slide 8: Tcelna in Secondary Progressive MS

    8 Tcelna in Secondary Progressive MS SPMS 450,000 Individuals in North America diagnosed with MS; 30-45 % potentially have an SPMS diagnosis Market Size: $7 Billion (est.) Relapsing Remitting MS; Clinically Isolated Syndrome; Primary Progressive MS Secondary Progressive MS market potential in North

  9. Slide 9: Tcelna Lead Program Targeting Secondary Progressive MS

    9 Tcelna® Lead Program Targeting Secondary Progressive MS patients Fast Track Designation by FDA Phase 2b is fully enrolled: 190 patients with SPMS Top line data expected in 2H 2016 Design Double-blind, 1:1 randomized, placebo-controlled 35 clinical sites in USA and Canada Two annual courses of pers

  10. Slide 10: Merck Serono Agreement

    10 Merck Serono Agreement Agreement signed 2013; strong potential partner Option and License Agreement for worldwide rights to all Multiple Sclerosis indications, excluding Japan If Merck Serono exercises option: Merck Serono to fund any Phase 3, pre-commercial and commercial activities Merck Serono

  11. Slide 11: Results and Explanation of RRMS & SPMS Clinical Trials

    RESULTS AND EXPLANATION OF RRMS & SPMS CLINICAL TRIALS

  12. Slide 12: Mechanism of Action: Reduction in Myelin Reactive T-Cells

    12 Mechanism of Action Reduction in Myelin Reactive T-Cells -100% -90% -80% -70% -60% -50% -40% -30% -20% -10% 0% Week 0 Week 5 Week 13 Week 21 Week 28 Week 52 Results from Tcelna dose ranging studies: Published in Clinical Immunology (2009) 131, 202-215 Reduction in MRTC Dose 2 Dose 3 Dose 4 Each d

  13. Slide 13: Phase 2b RRMS Prior Clinical Trial

    13 Phase 2b RRMS prior clinical trial Tcelna showed 37% improvement over placebo (mITT) (secondary endpoint measurement, primary MRI endpoint measure not met) 0.214 0.339 0 0.05 0.1 0.15 0.2 0.25 0.3 0.35 0.4 37% Reduction in Annualized Relapse Rate (ARR) Tcelna Placebo n=94 n=48 Relapses/Patient/Ye

  14. Slide 14: Phase 2b RRMS Prior Clinical Trial: Reversal of Disability

    14 Phase 2b RRMS Prior Clinical Trial Reversal of Disability in Prospective Analysis in More Active Patients Sub-population of patients (n=50) with more progressed/active disease profile (baseline ARR >1) 2.4 2.23 2.2 2.39 2.10 2.15 2.20 2.25 2.30 2.35 2.40 2.45 EDSS Score (Mean) Baseline Week 52 Tc

  15. Slide 15: Phase I/II SPMS Prior Clinical Trials

    15 Phase I/II SPMS Prior Clinical Trials Tcelna Stabilizes Disease in SPMS at 2 Years 80% 20% 40% 0% 20% 40% 60% 80% 100% Percent of Patients Showing Disease Stabilization Stabilization vs. Historical Progression Stable Progressed 80% of patients showed no further disease progression by EDSS at 2 ye

  16. Slide 16: IMMPATH: Proprietary Drug Development Platform

    IMMPATH® : PROPRIETARY DRUG DEVELOPMENT PLATFORM 16

  17. Slide 17: Single Cycle Manufacturing Process

    17 Single Cycle Manufacturing Process: Annual course of treatment (5 doses) from one blood draw Cryopreservation Formulation/ Irradiation of each dose as required Administration: 5 subcutaneous injections/year Manufacturing and QC Dispensation 35 days Epitope Profiling 1 day 14 days - Red Cross - Bl

  18. Slide 18: Expected Commercialization Model

    18 Expected Commercialization Model “Build-Out” not a “Scale-up” process Module C 10,000 patients Module B 10,000 patients Module A 10,000 patients Opexa fully owns and operates its cGMP Facility Modular design, allows for cost effective commercial scale out Focus on reduced Cost of Goods (COGS) sho

  19. Slide 19: OPX-212: Neuromyelitis Optica (NMO)

    OPX-212: NEUROMYELITIS OPTICA (NMO) 19

  20. Slide 20: Comprehensive Process to Determine Optimal Additional Indications

    Comprehensive Process to Determine Optimal Additional Indications for Opexa potential disease targets off platform addison's disease autoimmune hemolytic anemia celiac disease goodpasture's syndrome grave's disease hashimoto's thyroiditis idiotypic thrombocytopenic purpura myasthenia gravis neuromye

  21. Slide 21: NMO: A Rare Disease of the Central Nervous System

    21 NMO: A rare disease of the Central Nervous System Neuromyelitis optica (NMO) is a rare or orphan autoimmune disease Immune system cells and antibodies mistakenly attack and destroy myelin cells in the optic nerves and the spinal cord Individuals with NMO develop optic neuritis, which causes pain

  22. Slide 22: Disease Pathogenesis

    22 Disease Pathogenesis An astrocytopathic disease of the CNS characterized by optic neuritis, transverse myelitis; it is a B-cell-dependent disease associated with anti-aquaporin-4 antibodies NMO Pathogenic T-Cells Anti-AQP-4 Plasma Cell Binding to AQP4 channels on the astrocytes Increase astrocyte

  23. Slide 23: Potential Intervention Points for T-cell Therapy

    23 Potential Intervention Points for T-cell Therapy T-cell therapy believed to inhibit AQP-4 autoantibody, pro-inflammatory cytokines and prevent infiltration of macrophages and granulocytes Without the pathogenic T-cell, the B-cell does not signal the production of the AQP-4 antibody Possible resul

  24. Slide 24: NMO Investment Thesis

    24 NMO Investment Thesis Any therapy that could achieve tolerization of the AQP-4 reactive T-cells may offer a cure for NMO OPX-212 has the potential to address the root cause of NMO OPX-212 leverages Opexa’s T-cell platform to B-cell mediated orphan diseases Opexa currently retains world wide right

  25. Slide 25: Experienced Management Team and Board of Directors

    25 Experienced Management Team and Board of Directors NeilWarma, President & CEO, Director 19+ years international healthcare experience with large Pharma and emerging biotechnology companies Former Senior Management, Novartis Pharmaceuticals, Basel, Switzerland Former CEO, Viron Therapeutics, Inc.

  26. Slide 26: SPMS Scientific Advisory Board

    26 SPMS Scientific Advisory Board Dawn McGuire, M.D., FAAN (Chair) Advisory Council of the Gill Heart Institute Former Vice President of Clinical Research at Elan Pharmaceuticals Hans-Peter Hartung, M.D Chair of Neurology at Heinrich-Heine University, Düsseldorf Executive Board member of ECTRIMS, Wo

  27. Slide 27: Opexa Investment Thesis

    27 Opexa Investment Thesis PIPELINE Tcelna: Secondary Progressive MS, limited competition, $7BN potential market OPX-212: Recently launched development program in NMO, no approved therapies, orphan indication Precision Immunotherapy potentially optimizes benefit-risk profile VALIDATION Option agreem

Opexa Therapeutics — Investor Presentation (May 2015) on 6ix